Nurix Therapeutics (NRIX) Receivables - Other (2020 - 2026)

Nurix Therapeutics (NRIX) has reported Receivables - Other for 7 consecutive years, with $1.9 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Receivables - Other rose 11.76% year-over-year to $1.9 million; the TTM figure through May 2026 stood at $1.9 million (up 11.76% YoY), while the FY2025 annual figure was $1.5 million, changed 0.0% from the prior year.
• Receivables - Other fell to $1.9 million in Q2 2026 per NRIX's latest filing, from $2.4 million in the prior quarter.
• Across five years, Receivables - Other topped out at $2.4 million in Q1 2026 and bottomed at $600000.0 in Q2 2024.
• Historically, Receivables - Other has averaged $1.3 million across 5 years, with a median of $1.1 million in 2022.
• Annual changes were most pronounced in 2022 — Receivables - Other sank 78.0% — and 2025, when it soared 183.33%.
• Nurix Therapeutics' Receivables - Other stood at $1.1 million in 2022, then decreased by 27.27% to $800000.0 in 2023, then surged by 87.5% to $1.5 million in 2024, then changed by 0.0% to $1.5 million in 2025, then increased by 26.67% to $1.9 million in 2026.
• Business Quant data shows NRIX's Receivables - Other at $1.9 million in Q2 2026, $2.4 million in Q1 2026, and $1.5 million in Q4 2025.